# SS‑31 (elamipretide) film references

- [[1] Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. Journal of Biological Chemistry. 2004;279(33):34682–34690. PMID 15178689.](https://pubmed.ncbi.nlm.nih.gov/15178689/)
- [[2] Roshanravan B, Liu SZ, Ali AS, et al. In vivo mitochondrial ATP production is improved in older adult skeletal muscle after a single dose of elamipretide in a randomized trial. PLoS One. 2021;16(7):e0253849. PMID 34264994.](https://pubmed.ncbi.nlm.nih.gov/34264994/)
- [[3] U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. News release, September 19, 2025.](https://www.fda.gov/news-events/press-announcements/fda-grants-accelerated-approval-first-treatment-barth-syndrome)
- [[4] FORZINITY (elamipretide) injection, prescribing information, Stealth BioTherapeutics Inc. DailyMed. Sections 1, 5.2, 6.1 and 14. Checked November 21, 2026.](https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=146bf34c-76f2-48db-ac07-fb29cce2cd75)
